FDA Critical Path Office Would Define Up To Four “Opportunities” Per Year
FDA envisions creating an Office of Critical Path Opportunities over the next few months to coordinate with industry, academics, clinicians and the general public in proposing an annual list of translational research priorities to spur product development
More from Archive
More from Medtech Insight
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.